Anika Intangible Assets from 2010 to 2026
| ANIK Stock | USD 10.22 0.01 0.1% |
Intangible Assets | First Reported 2001-09-30 | Previous Quarter 1.7 M | Current Value 1.6 M | Quarterly Volatility 30.6 M |
Check Anika Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anika Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.8 M, Interest Expense of 2.8 M or Selling General Administrative of 67.1 M, as well as many indicators such as Price To Sales Ratio of 3.32, Dividend Yield of 0.0 or PTB Ratio of 1.71. Anika financial statements analysis is a perfect complement when working with Anika Therapeutics Valuation or Volatility modules.
Anika | Intangible Assets | Build AI portfolio with Anika Stock |
Historical Intangible Assets data for Anika Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Anika Therapeutics represents a compelling investment opportunity.
Latest Anika Therapeutics' Intangible Assets Growth Pattern
Below is the plot of the Intangible Assets of Anika Therapeutics over the last few years. It is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. Anika Therapeutics' Intangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anika Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Intangible Assets | 10 Years Trend |
|
Intangible Assets |
| Timeline |
Anika Intangible Assets Regression Statistics
| Arithmetic Mean | 22,732,544 | |
| Geometric Mean | 10,723,538 | |
| Coefficient Of Variation | 129.81 | |
| Mean Deviation | 21,218,399 | |
| Median | 10,635,000 | |
| Standard Deviation | 29,510,034 | |
| Sample Variance | 870.8T | |
| Range | 90.2M | |
| R-Value | 0.12 | |
| Mean Square Error | 914.9T | |
| R-Squared | 0.02 | |
| Significance | 0.64 | |
| Slope | 716,744 | |
| Total Sum of Squares | 13933.5T |
Anika Intangible Assets History
About Anika Therapeutics Financial Statements
Anika Therapeutics investors utilize fundamental indicators, such as Intangible Assets, to predict how Anika Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Intangible Assets | 2.9 M | 2.7 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Anika Therapeutics Correlation against competitors. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Anika Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.51) | Earnings Share (0.99) | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets |
Anika Therapeutics's market price often diverges from its book value, the accounting figure shown on Anika's balance sheet. Smart investors calculate Anika Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Anika Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Anika Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Anika Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.